Skip to main content

Surrozen, Inc. (SRZN)

NASDAQ: SRZN · Delayed Price · USD
+0.08 (1.16%)
After-hours:Oct 26, 2021 4:57 PM EDT
0.33 (5.01%)
At close: Oct 26, 4:00 PM
Market Cap246.64M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out8.06M
EPS (ttm)-5.70
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close6.59
Day's Range6.44 - 6.95
52-Week Range5.49 - 14.00
Price Targetn/a
Earnings Daten/a

About SRZN

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, ...

IndustryBlank Check / SPAC
Stock ExchangeNASDAQ
Ticker SymbolSRZN
Full Company Profile

Financial Performance

Financial Statements


Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related:   ...

2 weeks ago - Benzinga

Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week

Encouraging preclinical data support continued advancement of SZN-1326 towards first in human clinical studies in 2022 Encouraging preclinical data support continued advancement of SZN-1326 towards firs...

3 weeks ago - GlobeNewsWire

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, ...

1 month ago - GlobeNewsWire

Here's why Surrozen shares are up more than 50% on Tuesday

Almost a month after Surrozen Inc (NASDAQ: SRZN) completed its business combination with a special purpose acquisition company (SPAC), Consonance-HFW Acquisition Corp, Stifel assumed coverage of the bio...

1 month ago - Invezz

See Why Surrozen Stock Is Surging On Tuesday

Stifel initiated coverage of Surrozen Inc (NASDAQ: SRZN) with a Buy rating and $19 price target.  The regenerative medicine biotech started trading recently on NASDAQ via SPAC deal with Consonance-HFW A...

1 month ago - Benzinga

Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today ...

2 months ago - Business Wire

New Surrozen to Trade on Nasdaq as “SRZN”

PRINCETON, N.J.--(BUSINESS WIRE)--Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW) (“CHFW”) today announced that, upon the Domestication and the consummation of its pending business combinatio...

2 months ago - Business Wire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Consonance-HFW Acquisition Corp. - CHFW

NEW YORK, May 15, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action ...

5 months ago - PRNewsWire

INVESTIGATION ALERT: Halper Sadeh LLP Investigates CHFW, ROCC, AGC, TWCT, GLEO; Shareholders are Encouraged to Contac...

NEW YORK, April 29, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Consonance-HFW Acquisition Corp. (NYSE: CHFW)  concer...

Other symbols:AGCROCC
5 months ago - PRNewsWire

Consonance-HFW Acquisition Corp. Securities to Commence Separate Trading

PRINCETON, N.J.--(BUSINESS WIRE)--Consonance-HFW Acquisition Corp. (NYSE American LLC: CHFW.U) (“Consonance-HFW”) announced today that separate trading of its common stock and warrants underlying the Co...

9 months ago - Business Wire

Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering

NEW YORK--(BUSINESS WIRE)--Consonance-HFW Acquisition Corp. (“Consonance-HFW”) announced today the pricing of its initial public offering of 8,000,000 units, at a price to the public of $10.00 per unit,...

11 months ago - Business Wire